We are in an era that promises a rational. treatment of cancer patients. Levy et al. Genome Research 22:2201, 2012 Vanderbilt university
|
|
- Prosper Black
- 5 years ago
- Views:
Transcription
1 Enhancing Assessment of Leukemia with Next Generation Sequencing Michelle Afkhami, M.D. Medical Director, Clinical i l Molecular l Laboratory City of Hope National Medical Center How the Expert Treat Hematologic Malignancies
2 FINANCIAL DISCLOSURE NO CONFLICTS of INTEREST to DISCLOSE
3 We are in an era that promises a rational rather than empiric approaches for the treatment of cancer patients. Levy et al. Genome Research 22:2201, 2012 Vanderbilt university
4 The 20 Most Commonly Diagnosed Cancers Worldwide, 2012 Estimates
5 Estimated Number of new hematologic malignancies and deaths by sex, US, 2017 NAACCR*
6 Modern Pathologists Tissue pathology Molecular pathology MACRO HISTO/ CYTO IHC/ ICC IN SITU HYBRIDIZATIONS PCR Phenotype and Genotype are not mutually exclusive, but are complementary New molecular diagnostic approaches and New molecular diagnostic approaches and classifications are based on solid morphological interpretations
7 Genomic Landscapes of Common Forms of Human Cancer Average genes mutated 91% missense mutations 8% nonsense changes <2% splice site or UTR Bert Vogelstein et al. Science 2013;339:
8 Classification of leukemia was so easy before introduction of effective treatment Myeloid origin Acute Acute Myeloid Leukemia (AML) Chronic Chronic Myeloid Malignancies (CML, etc) Lymphoid origin Acute Lymphoblastic Leukemia (ALL) Chronic Lymphocytic Malignancies (CLL, etc)
9 Classification of leukemia was so easy before introduction of effective treatment Myeloid origin Acute Acute Myeloid Leukemia (AML) Chronic Chronic Myeloid Malignancies (CML, etc) Lymphoid origin Acute Lymphoblastic Leukemia (ALL) Chronic Lymphocytic Malignancies (CLL, etc)
10
11 Karyotype 46,XX,t(9;22)(q34;q11.2) - Philadelphia chromosome
12 Philadelphia chromosome: A breakthrough In 1960 the Philadelphia chromosome was first discovered by Peter Nowell and David Hungerford from University of Pennsylvania. In 1973, Janet Rowley identified the mechanism by which the Ph chromosome arises as a translocation at University of Chicago.
13 BCR-ABL1 Tyrosine Kinase Inhibitor In the late 1990s, a TKI, STI-571 (imatinib), ib) was identified by Novartis company. In 2000 Jon Kuriyan determined the mechanism by which STI-571 inhibits the BCR/Abl kinase domain. In 2001 it was marketed by Novartis as imatinib mesylate (Gleevec in the US, Glivec in Europe)
14 Classification is easy when there is NO effective treatment Broken leg: shoot Book of Equine Medicine Infected eye: shoot Splayed hoof: shoot Runny nose: shoot Fever: shoot
15 FISH showing the BCR (green), ABL (orange), and BCR-ABL fusion g (g ), ( g ), signals (arrow): A=positive (contains a residual ABL signal), B=normal
16 Historic Evaluation FLT3 NPM1 CEBPA Current Evaluation Evaluation Morphologic F t DNMT3A TET2 IDH1/ IDH2 Evaluation Features Fl KIT MLL WT1 BCOR Molecular profiling Flow Cytometric analysis FLT3 BCOR GATA2 RUNX1 TP53 NGS Cytogenetics and FISH analysis NPM1 CEBPA ASXL1 JAK2 EZH2 PCR analysis Molecular studies EVI1 CBL RAS RB1 studies RB1 MYC P16 MPL
17 Molecular Classification of leukemia Myeloid origin Lymphoid origin Acute FLT3, NPM1, KIT, CEBPA, IDH1, IDH2, ASXL1, DNMT3A, NRAS, RUNX1, TET2, TP53, ABL1 class fusion, CRLF2r_JAK2, JAK-STAT- EPORr- JAK2r, Chronic BCR/ABL (190,210,230) ATM, BIRC3, NOTCH1, SF3B1, TP53,
18 Is there still a role for microscopic evaluation in the diagnosis? Even in AML morphologic exam might be the quickest way for establishing a diagnosis Example: Quick diagnosis i of acute promyelocytic leukemia to start ATRA Does give information about cellularity, maturation patterns, stromal changes Establish baseline for evaluation of treatment efficacy Exclude relevant differential diagnoses
19 What is the molecular WHO update in AML classifications? Its incidence is expected to increase as the population ages. 1.2% of cancer deaths in the US.
20 AML FAB Classification: French-American-British Classification 1976 Eight major subtypes (M0 M7 ) Morphology and Cytochemistry t
21
22 The updated WHO 2016 Classification of AML AML, not otherwise specified (NOS) AML with recurrent genetic abnormalities AML with myelodysplasia-related changes Therapy-related myeloid neoplasms Myeloid sarcoma Myeloid proliferations related to Down syn
23 FAB (1976) Classification Connection to AML, NOS WHO 2008 category M0 AML with minimal differentiation M1 AML without maturation M2 AML with maturation M3 Acute Promyelocytic Leukemia M4 Acute Meylomonocytic Leukemia M5 Acute Monocytic/Monoblastic L. M6 Acute Erythroid Leukemia M7 Acute Megakaryoblastic Leukemia
24 AML, NOS WHO 2016 AML with minimal differentiation AML without maturation AML with maturation Acute monoblastic/monocytic Leukemia Pure Erythroid Leukemia Acute Megakaryoblastic Leukemia Acute Basophilic Leukemia Acute Panmyelosis with Myelofibrosis
25 AML with Recurrent genetic abnormality t(8;21);runx1-runx1t1 RUNX1T1 some maturation of neutrophilic line; rare in older patients; AML1/ETO fusion protein; FAB M2; flow cytometry CD19 t(15;17); PML-RARA: APL (granular and microgranular variants); t(11;17), t(5;17) inv(16) or t(16;16);cbfb-myh11 abnormal eosinophilic component; AMML with eos(m4eo) t(9;11); MLLT3- KMT2A (MLL) - monocytic; children; t(6;9); DEK-NUP214 Basophilia and multilinage dyplasia Inv3 or t(3;3); GATA2,MECOM t(1;22);rbm15-mkl1mkl1
26 Gene mutations for past 10 years Most commonly tested: FLT3 NPM1 Affecting DNA methylation: DNMT, TET, IDH, ASXL Tumor suppressor genes: TP53, WT1, NF1 Activated signaling: FLT3, RAS, NPM1
27 Two-hit model of leukemogenesis Loss of function of transcription factors needed for differentiation eg. AML1-ETO CBF -SMMHC PML-RAR Gain of function mutations of tyrosine kinases eg. FLT3, c-kit, NRAS, and K-RAS mutations BCR-ABL TEL-PDGF R Differentiation block + Enhanced proliferation AML Differentiation Leukemia
28
29 AML with mutated NPM1 Mutation of the exon 12 of the NPM1 gene. Aberrant cytoplasmic expression of nucleophosmin NPM1 mutations occur in 45 64% of adult AML with a normal karyotype Mutually exclusive with partial tandem duplications of MLL and CEBPA
30 NPM1 NPM1 + AML: Good response to induction therapy and has a favorable prognosis The coexistence of FLT3-ITD and NPM1 mutations ti is associated with a poorer prognosis, but still has an improved prognosis compared to AML that t is NPM1 - and FLT3-ITD +
31 Mutational landscape of AML with normal cytogenetics: Biological and clinical implications Maria Paola Martelli, Brunangelo Falini, et al. Institute te of Hematology, University of Perugia, Perugia, Italy Blood Reviews 27 (2013) FLT3-ITD loses its prognostic effect in CN- AML patients >60 years and especially those aged >70 years On the other hand, NPM1 mutations maintain their positive effect on clinical outcome in this age group
32 CEBPA CCAAT/enhancer binding protein alpha Occur in 6 15% of de novo AML and in 15 18% of CN-AML AML with mutated CEBPA tends to have Higher hemoglobin levels Lower platelet counts Lower lactate dehydrogenase levels Higher PB blast cell counts
33 AML with biallelic mutations of CEBPA AML with a normal karyotype yp and CEBPA mutation is associated with a favorable prognosis, similar to that of AML with inv(16)(p13.1q22) or t(8;21)(q22;q22). q )
34 AML with BCR-ABL1 AML with a normal karyotype yp and CEBPA mutation is associated with a favorable prognosis, similar to that of AML with inv(16)(p13.1q22) or t(8;21)(q22;q22). q )
35 FLT 3 -activating mutation fms-like tyrosine kinase 3 (FLT3) gene One of the most common molecular abnormality of AML A member of the PDGFR family Encodes a tyrosine kinase receptor that is involved in hematopoietic stem cell differentiation and proliferation.
36 FLT3 Extracellular domain Transmembrane and Juxtamembrane domains Tyrosine kinase domain Dimerization cause activation and recruits proteins leading to activation of AKT, MAPK, and STAT, which interact with HSP90 which protects them from inactivation and chaperones the active mediators to the nucleus to mediate vital cellular functions
37 DNMT3A Prediction of response to therapy (decitabine) in AML Found in 17-19% of AML
38
39 Top 20 genes in AML
40
41
42
43
44
45 Case 64 year-old female with pancytopenia PBS P t i ith 14% i l ti PBS: Pancytopenia with 14% circulating blasts
46 BM Aspirate
47 Bone marrow core biopsy
48 Diagnosis Bone marrow biopsy (HP15-861): Acute myeloid Leukemia (35.5% BLASTS) Flow cytometry: 38% blasts with CD13, CD34, CD117, and HLA-DR expression. IDH1/2 was ordered.
49 Next generation sequencing Yielding rapid and relatively low-cost data sets Introducing new prognostic markers in AML such as DNMT3A and IDH1
50 TOP 20 genes in Acute myeloid leukemia
51
52
53 Overview of CMDL at COH In operation since 1990s as a clinical reference laboratory CAP certified, CLIA licensed Clients: City of Hope Medical Center Last 3 years, 681 non-coh facilities from: United States, Canada, Mexico, Brazil, Belgium, Spain, Turkey, Iran, Israel, China, Egypt, Australia
54 Clinical Molecular Diagnostics Laboratory Services: Solid Tumors Hematological Malignancies Germline Testing Molecular Microbiology
55 Molecular Testing at CMDL, COH CLIA & CAP Certified Laboratory Application of molecular techniques & knowledge of the molecular mechanisms of disease in: Diagnosis Prognosis Treatment
56 Molecular Testing BRAF V600E BRAF V600E BRAF V600E
57 Targeted next generation sequencing of clinically significant gene mutations and translocations in leukemia Eric J Duncavage, Haley J Abel, Philippe Szankasi, Todd W Kelley, and John D Pfeifer Modern Pathology (2012) 25,
58 Leukemias are currently subclassified based on the presence of recurrent cytogenetic abnormalities and gene mutations. Basis for risk-adapted therapy
59 Targeted next generation sequencing Full spectrum of prognostically significant gene mutations including: Translocations, Single nucleotide variants (SNVs) Insertions/deletions (indels) Can be identified simultaneously in multiplexed sequence data. Yielding rapid and relatively low cost data Yielding rapid and relatively low-cost data sets
60 PCR and Sanger sequencing Commonly tested genes: FLT3 and NPM1 tend to have a limited spectrum of mutations, making them amenable to PCR The broader range of mutations such as CEPBA, DNMT3A, and KIT needs the use of direct sequencing Adding to the expense and turn-around time of testing.
61 FISH Detection of recurrent, balanced chromosomal translocations is critical to leukemia prognosis FISH offers increased sensitivity over conventional cytogenetics But Unable to identify novel translocation partners, such as those involving the MLL locus, or variant breakpoints Requires the use of multiple probes again Requires the use of multiple probes, again increasing the cost and complexity of testing
62 2 d Generation NGS Platforms CMDL Targeted sequencing Life Technology Ion Torrent Up to Gb per run Fast: 4-24 hours Depth of coverage >1000x Simplified data analysis Illumina MiSeq
63
64 Hematological Malignancies Hematological Malignancies NGS panel Myeloid neoplasms Lymphoid neoplasms
65 Hematological Malignancies: Mutation assay by NGS of 74 genes OncoHemeMutations ASXL1 CCND1 EP300 IDH1 KMT2D NRAS SF3B1 WHSC1L1 ATM CCND3 ETV6 IDH2 KRAS PAX5 SPI1 WT1 BCOR CD79A EZH2 IL7R MEF2B PDGFRA SRSF2 ZRSR2 BIRC3 CD79B FBXW7 JAK1 MIR142 PHF6 STAG2 BRAF CDKN2A FLT3 JAK2 MPL PIK3CA SUZ12 BTK CEBPA GATA1 JAK3 MYC PTEN TCF3 CALR CHEK2 GATA2 KDM6A MYD88 PTPN1 TET2 CARD11 CREBBP HRAS KIT NOTCH1 PTPN11 TP53 CBL CSF3R ID3 KMT2A NOTCH2 RUNX1 U2AF1 CBLB DNMT3A IKZF1 KMT2C NPM1 SETBP1 WHSC1
66 Mini OncoHem NGS Assay Mutation analysis by Next Generation Sequencing Peripheral blood, bone marrow, and formalin-fixed paraffin-embedded tissue (FFPE) NPM1 KIT IDH1 IDH2 JAK2 MPL BRAF ABL1
67 Mini OncoHeme e Assay CEBPA by Sanger Sequencing NPM1 by PCR FLT3 TKD and ITD with signal ratio by PCR
68 Hematological Malignancies: Fusion Assay by NGS of f23 genes OncoHemeFusions ABL1 ABL2 ALK BCR CBFB CRLF2 CSFIR FGFR1 JAK2 KMT2A MECOM MKL1 NOTCH1 NUP214 PDGFRA PDGFRB PICALM RARA RBM15 RUNX1 RUNX1T1 TAL1 TCF3
69 Other Hematological Malignancies Assays PCR assays Immunoglobulin heavy and light chain gene rearrangements with BIOMED-2 primers T-cell receptor gamma and beta chain gene rearrangements with BIOMED-2 primers Quantitative t(9:22); BCR/ABL1 Quantitative t(15;17); PML/RARA Inv 16 t(8;21) t(14;18) Calreticulin (CALR) mutations
70 NGS Germline Cancer Predisposition Panels Targeted to breast, colon, ovary, pancreas, & kidney APC ATM BAP1 BARD1 BLM BMPR1A BRCA1 BRCA2 BRIP1 CDH1 CDK4 CDKN2A CHEK2 CTNNA1 EPCAM FAM175A FANCC FH FLCN HOXB13 MET MLH1 MRE11 MSH2 MSH6 MUTYH NBN PALB2 PMS2 PTEN RAD50 RAD51C RAD51D SDHB SDHC SDHD SMAD4 STK11 TP53 TSC1 TSC2 VHL XRCC2 Hong et al, AMP 2015 National Meeting Telatar et al, AMP 2015 National Meeting
71 Next.?
72 Era of Precision Medicine Tissue-based diagnosis still has the central role in diagnosis.
73 Proposed testing algorithm Targeted Mutation Panels genes: Mutations, deletions, gene fusions First line of testing Low cost/better reimbursement Mutation/ fusions + Mutation - Targeted Therapy Whole exome and transcriptome analysis Search for novel and unexpected variants Rare fusion types, splicing variants Copy number changes
74 So many genes, so little time. Communication for Collaboration Genomic Tumor boards Disease Teams/Programs Phase 1 Therapeutics meeting Inservice training for mid-levels Biannual review of existing clinical tests Collaborations with BRI researchers through the Molecular Core
75 NGS data analysis requires integration of clinical,,pathological, and genetic interpretations: Multidisciplinary Genomic Tumor Board
76 Things you can count on Death Taxes A new lymphoma/ leukemia classification based on new molecular l findings!
77
Enhancing Assessment of Myeloid Disorders in the Era of Precision Medicine
Enhancing Assessment of Myeloid Disorders in the Era of Precision Medicine Michelle Afkhami, M.D. Medical Director, Clinical Molecular Diagnostic Laboratory City of Hope National Medical Center Objectives
More informationObjectives and Financial Disclosure
Enhancing Assessment of Leukemia and Lymphoma with Next Generation Sequencing Michelle Afkhami, M.D. Medical Director, Clinical Molecular Laboratory Assistant Professor, Department of Pathology City of
More informationPatricia Aoun MD, MPH Professor and Vice-Chair for Clinical Affairs Medical Director, Clinical Laboratories Department of Pathology City of Hope
Patricia Aoun MD, MPH Professor and Vice-Chair for Clinical Affairs Medical Director, Clinical Laboratories Department of Pathology City of Hope National Medical Center Disclosures I have no disclosures
More informationOut-Patient Billing CPT Codes
Out-Patient Billing CPT Codes Updated Date: August 3, 08 Client Billed Molecular Tests HPV DNA Tissue Testing 8764 No Medicare Billed - Molecular Tests NeoARRAY NeoARRAY SNP/Cytogenetic No 89 NeoLAB NeoLAB
More informationMolecular. Oncology & Pathology. Diagnostic, Prognostic, Therapeutic, and Predisposition Tests in Precision Medicine. Liquid Biopsy.
Molecular Oncology & Pathology Hereditary Cancer Somatic Cancer Liquid Biopsy Next-Gen Sequencing qpcr Sanger Sequencing Diagnostic, Prognostic, Therapeutic, and Predisposition Tests in Precision Medicine
More informationThe Center for PERSONALIZED DIAGNOSTICS
The Center for PERSONALIZED DIAGNOSTICS Precision Diagnostics for Personalized Medicine A joint initiative between The Department of Pathology and Laboratory Medicine & The Abramson Cancer Center The (CPD)
More informationEnhancing Assessment of Myeloid Leukemia in the Era of Precision Medicine
Enhancing Assessment of Myeloid Leukemia in the Era of Precision Medicine Michelle Afkhami, M.D. Medical Director, Clinical Molecular Diagnostic Laboratory City of Hope National Medical Center How the
More informationNeoTYPE Cancer Profiles
NeoTYPE Cancer Profiles Multimethod Analysis of 25+ Hematologic Diseases and Solid Tumors Anatomic Pathology FISH Molecular The next generation of diagnostic, prognostic, and therapeutic assessment NeoTYPE
More informationEnhancing Assessment of Myeloid Leukemia in the Era of Precision Medicine
Enhancing Assessment of Myeloid Leukemia in the Era of Precision Medicine Michelle Afkhami, M.D. Medical Director, Clinical Molecular Diagnostic Laboratory City of Hope National Medical Center How the
More informationUpdate on the WHO Classification of Acute Myeloid Leukemia. Kaaren K. Reichard, MD Mayo Clinic Rochester
Update on the WHO Classification of Acute Myeloid Leukemia Kaaren K. Reichard, MD Mayo Clinic Rochester reichard.kaaren@mayo.edu Nothing to disclose Conflict of Interest Objectives Present a practical
More informationAugust 17, Dear Valued Client:
August 7, 08 Re: CMS Announces 6-Month Period of Enforcement Discretion for Laboratory Date of Service Exception Policy Under the Medicare Clinical Laboratory Fee Schedule (the 4 Day Rule ) Dear Valued
More informationNext Generation Sequencing in Haematological Malignancy: A European Perspective. Wolfgang Kern, Munich Leukemia Laboratory
Next Generation Sequencing in Haematological Malignancy: A European Perspective Wolfgang Kern, Munich Leukemia Laboratory Diagnostic Methods Cytomorphology Cytogenetics Immunophenotype Histology FISH Molecular
More informationMolecular Markers in Acute Leukemia. Dr Muhd Zanapiah Zakaria Hospital Ampang
Molecular Markers in Acute Leukemia Dr Muhd Zanapiah Zakaria Hospital Ampang Molecular Markers Useful at diagnosis Classify groups and prognosis Development of more specific therapies Application of risk-adjusted
More informationBlastic Plasmacytoid Dendritic Cell Neoplasm with DNMT3A and TET2 mutations (SH )
Blastic Plasmacytoid Dendritic Cell Neoplasm with DNMT3A and TET2 mutations (SH2017-0314) Habibe Kurt, Joseph D. Khoury, Carlos E. Bueso-Ramos, Jeffrey L. Jorgensen, Guilin Tang, L. Jeffrey Medeiros, and
More informationReporting cytogenetics Can it make sense? Daniel Weisdorf MD University of Minnesota
Reporting cytogenetics Can it make sense? Daniel Weisdorf MD University of Minnesota Reporting cytogenetics What is it? Terminology Clinical value What details are important Diagnostic Tools for Leukemia
More informationExamining Genetics and Genomics of Acute Myeloid Leukemia in 2017
Examining Genetics and Genomics of Acute Myeloid Leukemia in 2017 Elli Papaemmanuil, PhD Memorial Sloan Kettering Cancer Center New York, New York, United States Today s Talk Cancer genome introduction
More informationNeoTYPE Cancer Profiles
NeoTYPE Cancer Profiles 30+ Multimethod Assays for Hematologic Diseases and Solid Tumors Molecular FISH Anatomic Pathology The next generation of diagnostic, prognostic, and therapeutic assessment What
More informationIllumina Trusight Myeloid Panel validation A R FHAN R A FIQ
Illumina Trusight Myeloid Panel validation A R FHAN R A FIQ G E NETIC T E CHNOLOGIST MEDICAL G E NETICS, CARDIFF To Cover Background to the project Choice of panel Validation process Genes on panel, Protocol
More informationWHO Classification of Myeloid Neoplasms with Defined Molecular Abnormalities
WHO Classification of Myeloid Neoplasms with Defined Molecular Abnormalities Robert W. McKenna, M.D. 1/2009 WHO Classification of Myeloid Neoplasms (4th Edition)--2008 Incorporates new information that
More informationAML: WHO classification, biology and prognosis. Dimitri Breems, MD, PhD Internist-Hematoloog Ziekenhuis Netwerk Antwerpen
AML: WHO classification, biology and prognosis Dimitri Breems, MD, PhD Internist-Hematoloog Ziekenhuis Netwerk Antwerpen Acute myeloid leukemia Clonal expansion of undifferentiated myeloid precursors Impaired
More informationTest Name Results Units Bio. Ref. Interval. Positive
LL - LL-ROHINI (NATIONAL REFERENCE 135091534 Age 36 Years Gender Female 1/9/2017 120000AM 1/9/2017 105316AM 2/9/2017 104147AM Ref By Final LEUKEMIA GENETIC ROFILE ANY SIX MARKERS, CR QUALITATIVE AML ETO
More informationMolecular Advances in Hematopathology
Molecular Advances in Hematopathology HOW MOLECULAR METHODS HAVE CHANGED MY PRACTICE Objectives Understand the importance of cytogenetic/molecular studies in hematolymphoid diseases Know some of the important
More informationTargeted Agent and Profiling Utilization Registry (TAPUR ) Study. February 2018
Targeted Agent and Profiling Utilization Registry (TAPUR ) Study February 2018 Precision Medicine Therapies designed to target the molecular alteration that aids cancer development 30 TARGET gene alterations
More informationTest Name Results Units Bio. Ref. Interval. Positive
LL - LL-ROHINI (NATIONAL REFERENCE 135091533 Age 28 Years Gender Male 1/9/2017 120000AM 1/9/2017 105415AM 4/9/2017 23858M Ref By Final LEUKEMIA DIAGNOSTIC COMREHENSIVE ROFILE, ANY 6 MARKERS t (1;19) (q23
More informationObjectives. Morphology and IHC. Flow and Cyto FISH. Testing for Heme Malignancies 3/20/2013
Molecular Markers in Hematologic Malignancy: Ways to locate the needle in the haystack. Objectives Review the types of testing for hematologic malignancies Understand rationale for molecular testing Marcie
More informationGENETICS OF HEMATOLOGICAL MALIGNANCIES
de DUVE INSTITUTE GENETICS OF HEMATOLOGICAL MALIGNANCIES INTERUNIVERSITY CERTIFICATE IN HUMAN GENETICS Université catholique de Louvain Brussels,19/02/2016 Professor Hélène Antoine-Poirel, MD, PhD Center
More informationJennifer Hauenstein Oncology Cytogenetics Emory University Hospital Atlanta, GA
Comparison of Genomic Coverage using Affymetrix OncoScan Array and Illumina TruSight Tumor 170 NGS Panel for Detection of Copy Number Abnormalities in Clinical GBM Specimens Jennifer Hauenstein Oncology
More informationInitial Diagnostic Workup of Acute Leukemia
Initial Diagnostic Workup of Acute Leukemia Guideline from the College of American Pathologists (CAP) and the American Society of Hematology (ASH) Publication: Archives of Pathology and Laboratory Medicine
More informationJuan Ma 1, Jennifer Dunlap 2, Lisong Shen 1, Guang Fan 2 1
Juan Ma 1, Jennifer Dunlap 2, Lisong Shen 1, Guang Fan 2 1 Xin Hua Hospital, Shanghai, China 2 Oregon Health & Science University, Portland, OR, United States AML is a hematopoietic neoplasms characterized
More informationIllumina s Cancer Research Portfolio and Dedicated Workflows
Illumina s Cancer Research Portfolio and Dedicated Workflows Michael Sohn Clinical Sales Specialist Spain&Italy 2017 2017 Illumina, Inc. All rights reserved. Illumina, 24sure, BaseSpace, BeadArray, BlueFish,
More informationKrishna Reddy CH and Ashwin Dalal. Diagnostics Division, Centre for DNA Fingerprinting and Diagnostics, Hyderabad
Clinical Cytogenetics in the Diagnosis and Prognosis of Leukemias Krishna Reddy CH and Ashwin Dalal Diagnostics Division, Centre for DNA Fingerprinting and Diagnostics, Hyderabad Email: krishnareddy.chr@gmail.com
More informationAcute Myeloid Leukemia with RUNX1 and Several Co-mutations
Case SH2017-0281 Acute Myeloid Leukemia with RUNX1 and Several Co-mutations James Bauer, MD, PhD David Yang, MD Erik Ranheim, MD, PhD Catherine Leith, MB, Bchir Clinical History Chief Complaint: 72 year
More informationPlease Silence Your Cell Phones. Thank You
Please Silence Your Cell Phones Thank You Utility of NGS and Comprehensive Genomic Profiling in Hematopathology Practice Maria E. Arcila M.D. Memorial Sloan Kettering Cancer Center New York, NY Disclosure
More informationTreatments and Current Research in Leukemia. Richard A. Larson, MD University of Chicago
Treatments and Current Research in Leukemia Richard A. Larson, MD University of Chicago 2 Acute (rapid progression) Myeloid Acute myeloid leukemia (AML) Acute promyelocytic leukemia (APL) Lymphoid Acute
More informationCentoCancer STRIVE FOR THE MOST COMPLETE INFORMATION
CentoCancer STRIVE FOR THE MOST COMPLETE INFORMATION CentoCancer our most comprehensive oncogenetics panel for hereditary mutations Hereditary pathogenic variants confer an increased risk of developing
More informationLaboratory Service Report
Client C7028846-DLP Rochester Rochester, N 55901 Specimen Type Peripheral blood CR PDF Report available at: https://test.mmlaccess.com/reports/c7028846-zwselwql7p.ashx Indication for Test DS CR Pathogenic
More informationEnabling Personalized
Molecular Enabling Personalized Diagnostics Medicine- Targeted Sequencing: NGS-based solutions Silvia Dorn Roel Reinders- Andreas Diplas Friday, 19.06.2015 Company Overview Founded in April 2011 Development
More information5/21/2018. Disclosures. Objectives. Normal blood cells production. Bone marrow failure syndromes. Story of DNA
AML: Understanding your diagnosis and current and emerging treatments Nothing to disclose. Disclosures Mohammad Abu Zaid, MD Assistant Professor of Medicine Indiana University School of Medicine Indiana
More informationWest Midlands Regional Genetics Laboratory
West Midlands Regional Genetics Laboratory Haemato-oncology service update letter October 2017 Dear colleagues, We are writing to outline the latest developments to our service, aiming to support the management
More informationJordi Esteve Hospital Clínic (Barcelona) Acute Leukemia Working Party. The European Group for Blood and Marrow Transplantation
36th EBMT & 9th Data Management Group Annual Meeting Vienna, 23 March 2010 Jordi Esteve Hospital Clínic (Barcelona) Acute Leukemia Working Party The European Group for Blood and Marrow Transplantation
More informationGermline Multigene Panel Testing in Oncology: Genetic Counseling Perspective
Germline Multigene Panel Testing in Oncology: Genetic Counseling Perspective Sarah L. Campian, MS CGC Certified Genetic Counselor Nancy & James Grosfeld Cancer Genetics Center Objectives Identify patients/families
More informationTEST MENU TEST CPT CODES TAT. Chromosome Analysis Bone Marrow x 2, 88264, x 3, Days
TEST MENU CANCER/LEUKEMIA CHROMOSOME ANALYSIS Chromosome Analysis Bone Marrow 88237 x 2, 88264, 88280 x 3, 88291 4 Days Chromosome Analysis Bone Marrow Core 88237 x 2, 88264, 88280 x 3, 88291 4 Days Chromosome
More informationAcute leukemia and myelodysplastic syndromes
11/01/2012 Post-ASH meeting 1 Acute leukemia and myelodysplastic syndromes Peter Vandenberghe Centrum Menselijke Erfelijkheid & Afdeling Hematologie, UZ Leuven 11/01/2012 Post-ASH meeting 2 1. Acute myeloid
More informationClick to edit Master /tle style
Click to edit Master /tle style Tel: (314) 747-7337 Toll Free: (866) 450-7697 Fax: (314) 747-7336 Email: gps@wustl.edu Website: gps.wustl.edu GENETIC TESTING IN CANCER Ka/nka Vigh-Conrad, PhD Genomics
More informationAcute myeloid leukemia. M. Kaźmierczak 2016
Acute myeloid leukemia M. Kaźmierczak 2016 Acute myeloid leukemia Malignant clonal disorder of immature hematopoietic cells characterized by clonal proliferation of abnormal blast cells and impaired production
More informationADRL Advanced Diagnostics Research Laboratory
ADRL Advanced Diagnostics Research Laboratory John DeCoteau, MD FRCP Department of Pathology, Division of Hematopathology University of Saskatchewan Saskatchewan Cancer Agency ADRL Project Objectives New
More informationCurrent Techniques in Molecular Biology Friedel Nollet, Ph.D.
Current Techniques in Molecular Biology Friedel Nollet, Ph.D. Molecular Biology and Cytometry course May 16-17, 2013 Mol, SCK-CEN, Belgium Sanger DNA sequencing Kary Mullis received a Nobel Prize in chemistry
More informationGenomic Medicine: What every pathologist needs to know
Genomic Medicine: What every pathologist needs to know Stephen P. Ethier, Ph.D. Professor, Department of Pathology and Laboratory Medicine, MUSC Director, MUSC Center for Genomic Medicine Genomics and
More informationMolecular Markers. Marcie Riches, MD, MS Associate Professor University of North Carolina Scientific Director, Infection and Immune Reconstitution WC
Molecular Markers Marcie Riches, MD, MS Associate Professor University of North Carolina Scientific Director, Infection and Immune Reconstitution WC Overview Testing methods Rationale for molecular testing
More informationCase 1. Sa A.Wang, MD UT MD Anderson Cancer Center Houston, TX
Case 1 Sa A.Wang, MD UT MD Anderson Cancer Center Houston, TX Disclosure of Relevant Financial Relationships The USCAP requires that anyone in a position to influence or control the content of all CME
More informationConcomitant WT1 mutations predicted poor prognosis in CEBPA double-mutated acute myeloid leukemia
Concomitant WT1 mutations predicted poor prognosis in CEBPA double-mutated acute myeloid leukemia Feng-Ming Tien, Hsin-An Hou, Jih-Luh Tang, Yuan-Yeh Kuo, Chien-Yuan Chen, Cheng-Hong Tsai, Ming Yao, Chi-Cheng
More informationMOLECULAR SERVICES. mlabs.umich.edu
MOLECULAR SERVICES mlabs.umich.edu 800.862.7284 PICTURED ON LEFT IS MARWAN TAYEH, PH.D, CLINICAL ASSISTANT PROFESSOR, PEDIATRICS - GENETICS, ON RIGHT IS TODD ACKLEY, LABORATORY MANAGER MLabs is a full-service
More informationDisclosure: Objectives/Outline. Leukemia: Genealogy of Pathology Practice: Old Diseases New Expectations. Nothing to disclose.
RC1 Leukemia: Genealogy of Pathology Practice: Old Diseases New Expectations RC2 Disclosure: Nothing to disclose Henry Moon Lecture: UCSF Annual Conference Kathryn Foucar, MD kfoucar@salud.unm.edu May
More informationPlasma-Seq conducted with blood from male individuals without cancer.
Supplementary Figures Supplementary Figure 1 Plasma-Seq conducted with blood from male individuals without cancer. Copy number patterns established from plasma samples of male individuals without cancer
More informationCase #1. 65 yo man with no prior history presented with leukocytosis and circulating blasts: Bone marrow biopsy was performed
Case #1 65 yo man with no prior history presented with leukocytosis and circulating blasts: WBC 187.4K/uL ; Hgb 10.0gm/dL; Platelet 68K/uL Neutrophil % 25.0% Lymphocyte % 38.0% Monocyte % 12.0% Metamyelocyte
More informationJocelyn Chapman, MD Division of Gynecologic Oncology. Julie S. Mak, MS, MSc Genetic Counselor Hereditary Cancer Clinic
Jocelyn Chapman, MD Division of Gynecologic Oncology Julie S. Mak, MS, MSc Genetic Counselor Hereditary Cancer Clinic Genetics underlies all cancers Somatic or tumor genetics Germline or inherited genetics
More informationLaboratory Service Report
Specimen Type Peripheral blood CR PDF Report available at: https://test.mmlaccess.com/reports/c7028846-ih2xuglwpq.ashx Indication for Test DS CR Pathogenic utations Detected CR 1. JAK2: c.1849g>t;p.val617phe
More informationOpportunities for Optimal Testing in the Myeloproliferative Neoplasms. Curtis A. Hanson, MD
Opportunities for Optimal Testing in the Myeloproliferative Neoplasms Curtis A. Hanson, MD 2013 MFMER slide-1 DISCLOSURES: Relevant Financial Relationship(s) None Off Label Usage None 2013 MFMER slide-2
More informationSupplemental Material. The new provisional WHO entity RUNX1 mutated AML shows specific genetics without prognostic influence of dysplasia
Supplemental Material The new provisional WHO entity RUNX1 mutated AML shows specific genetics without prognostic influence of dysplasia Torsten Haferlach, 1 Anna Stengel, 1 Sandra Eckstein, 1 Karolína
More informationBeyond the CBC Report: Extended Laboratory Testing in the Evaluation for Hematologic Neoplasia Disclosure
Beyond the CBC Report: Extended Laboratory Testing in the Evaluation for Hematologic Neoplasia Disclosure I am receiving an honorarium from Sysmex for today s presentation. 1 Determining the Etiology for
More informationPrecision Oncology: Experience at UW
Precision Oncology: Experience at UW Colin Pritchard MD, PhD University of Washington, Department of Lab Medicine WSMOS Meeting November 1, 2013 Conflict of Interest Disclosures I declare the following,
More informationApplication of Whole Genome Microarrays in Cancer: You should be doing this test!!
Application of Whole Genome Microarrays in Cancer: You should be doing this test!! Daynna Wolff, Ph.D. Director, Cytogenetics and Genomics Disclosures Clinical Laboratory Director and Employee, Medical
More informationImpact of Biomarkers in the Management of Patients with Acute Myeloid Leukemia
Impact of Biomarkers in the Management of Patients with Acute Myeloid Leukemia Hartmut Döhner Medical Director, Department of Internal Medicine III Director, Comprehensive Cancer Center Ulm Ulm University,
More informationNext Generation Sequencing in Clinical Practice: Impact on Therapeutic Decision Making
Next Generation Sequencing in Clinical Practice: Impact on Therapeutic Decision Making November 20, 2014 Capturing Value in Next Generation Sequencing Symposium Douglas Johnson MD, MSCI Vanderbilt-Ingram
More informationAPPLICATIONS OF NEXT GENERATION SEQUENCING IN SOLID TUMORS - PATHOLOGIST PROSPECTIVE
AMP COMPANION MEETING SYMPOSIUM AT USCAP 2015 NEXT-GENERATION OF PATHOLOGY: ROLE OF PATHOLOGIST IN NGS-BASED PERSONALIZED MEDICINE APPLICATIONS OF NEXT GENERATION SEQUENCING IN SOLID TUMORS - PATHOLOGIST
More informationTest Name Results Units Bio. Ref. Interval. Positive
Lab No 135091548 Age 35 Years Gender Female 1/9/2017 120000AM 1/9/2017 103420AM 4/9/2017 23753M Ref By Dr UNKNWON Final Test Results Units Bio Ref Interval LEUKEMIA DIAGNOSTIC COMREHENSIVE ROFILE 3 t (1;19)
More informationSureSelect Cancer All-In-One Custom and Catalog NGS Assays
SureSelect Cancer All-In-One Custom and Catalog NGS Assays Detect all cancer-relevant variants in a single SureSelect assay SNV Indel TL SNV Indel TL Single DNA input Single AIO assay Single data analysis
More informationPredictive biomarker profiling of > 1,900 sarcomas: Identification of potential novel treatment modalities
Predictive biomarker profiling of > 1,900 sarcomas: Identification of potential novel treatment modalities Sujana Movva 1, Wenhsiang Wen 2, Wangjuh Chen 2, Sherri Z. Millis 2, Margaret von Mehren 1, Zoran
More informationThe Next Generation of Hereditary Cancer Testing
The Next Generation of Hereditary Cancer Testing Why Genetic Testing? Cancers can appear to run in families. Often this is due to shared environmental or lifestyle patterns, such as tobacco use. However,
More informationAccel-Amplicon Panels
Accel-Amplicon Panels Amplicon sequencing has emerged as a reliable, cost-effective method for ultra-deep targeted sequencing. This highly adaptable approach is especially applicable for in-depth interrogation
More informationMolecular Diagnostics of Myeloid and Lymphoid Neoplasms
Molecular Diagnostics of Myeloid and Lymphoid Neoplasms Molecular Pathology: Principles in Clinical Practice - 2012 John Greg Howe Ph.D. Department of Laboratory Medicine Yale University School of Medicine
More informationNext generation sequencing analysis - A UK perspective. Nicholas Lea
Next generation sequencing analysis - A UK perspective Nicholas Lea King s HMDC LMH is part of an integrated pathology service at King s Haematological Malignancy Diagnostic Centre (HMDC) HMDC serves population
More informationCLINICAL UTILITY OF INTEGRATED GENOMIC PROFILING IN PEDIATRIC LEUKEMIA
CLINICAL UTILITY OF INTEGRATED GENOMIC PROFILING IN PEDIATRIC LEUKEMIA FUMIN LIN, Ph.D. LINF1@EMAIL.CHOP.EDU CANCER GENOMIC DIAGNOSTIC LABORATORY DIVISION OF GENOMIC DIAGNOSTICS 1 PEDIATRIC LEUKEMIA Common
More informationIntelliGENSM. Integrated Oncology is making next generation sequencing faster and more accessible to the oncology community.
IntelliGENSM Integrated Oncology is making next generation sequencing faster and more accessible to the oncology community. NGS TRANSFORMS GENOMIC TESTING Background Cancers may emerge as a result of somatically
More informationDiagnostic Approach for Eosinophilia and Mastocytosis. Curtis A. Hanson, M.D.
Diagnostic Approach for Eosinophilia and Mastocytosis Curtis A. Hanson, M.D. 2014 MFMER slide-1 DISCLOSURES: Relevant Financial Relationship(s) None Off Label Usage None 2014 MFMER slide-2 Molecular Classification
More informationMolecular Hematopathology Leukemias I. January 14, 2005
Molecular Hematopathology Leukemias I January 14, 2005 Chronic Myelogenous Leukemia Diagnosis requires presence of Philadelphia chromosome t(9;22)(q34;q11) translocation BCR-ABL is the result BCR on chr
More informationPediatric Oncology & Pathology Services
Pediatric Oncology & Pathology Services Anatomic Pathology Flow Cytometry Cytogenetics Pharma Services Diagnostic, Prognostic, Predictive, and Predisposition Testing Pediatric Oncology & Pathology Services
More informationDiagnostic Molecular Pathology of Myeloid Neoplasms
Diagnostic Molecular Pathology of Myeloid Neoplasms Beirut, Lebanon Tuesday November 29, 2011: Pre-congress workshop Adam Bagg University of Pennsylvania Philadelphia, USA Myeloid neoplasms Myeloproliferative
More informationFluxion Biosciences and Swift Biosciences Somatic variant detection from liquid biopsy samples using targeted NGS
APPLICATION NOTE Fluxion Biosciences and Swift Biosciences OVERVIEW This application note describes a robust method for detecting somatic mutations from liquid biopsy samples by combining circulating tumor
More informationCost-Effective Strategies in the Workup of Hematologic Neoplasm. Karl S. Theil, Claudiu V. Cotta Cleveland Clinic
Cost-Effective Strategies in the Workup of Hematologic Neoplasm Karl S. Theil, Claudiu V. Cotta Cleveland Clinic In the past 12 months, we have not had a significant financial interest or other relationship
More informationMSI positive MSI negative
Pritchard et al. 2014 Supplementary Figure 1 MSI positive MSI negative Hypermutated Median: 673 Average: 659.2 Non-Hypermutated Median: 37.5 Average: 43.6 Supplementary Figure 1: Somatic Mutation Burden
More informationMixed Phenotype Acute Leukemias
Mixed Phenotype Acute Leukemias CHEN GAO; AMY M. SANDS; JIANLAN SUN NORTH AMERICAN JOURNAL OF MEDICINE AND SCIENCE APR 2012 VOL 5 NO.2 INTRODUCTION Most cases of acute leukemia can be classified based
More informationIntroduction of an NGS gene panel into the Haemato-Oncology MPN service
Introduction of an NGS gene panel into the Haemato-Oncology MPN service Dr. Anna Skowronska, Dr Jane Bryon, Dr Samuel Clokie, Dr Yvonne Wallis and Professor Mike Griffiths West Midlands Regional Genetics
More informationMolecular Genetic Testing for the Diagnosis of Haematological Malignancies
Molecular Genetic Testing for the Diagnosis of Haematological Malignancies Dr Anthony Bench Haemto-Oncology Diagnostic Service Cambrıdge Unıversıty Hospitals NHS Foundatıon Trust Cambridge UK Molecular
More informationOverview. Methods 9/11/2017. Next Generation Sequencing and Precision Medicine in Hematological Malignancies. Genotyping in hematology
Overview Next Generation Sequencing and Precision Medicine in Hematological Malignancies Sharathkumar Bhagavathi, MD University of Iowa Carver College of Medicine NGS as a genotyping platform in hematopathology
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Patel JP, Gönen M, Figueroa ME, et al. Prognostic relevance
More informationRole of FISH in Hematological Cancers
Role of FISH in Hematological Cancers Thomas S.K. Wan PhD,FRCPath,FFSc(RCPA) Honorary Professor, Department of Pathology & Clinical Biochemistry, Queen Mary Hospital, University of Hong Kong. e-mail: wantsk@hku.hk
More informationMeeting VAKB 8 februari 2011 Nancy Boeckx, MD, PhD
Meeting VAKB 8 februari 2011 Nancy Boeckx, MD, PhD What is it? clonal expansion of myeloid precursor cells with reduced capacity to differentiate as opposed to ALL/CLL, it is limited to the myeloid cell
More informationThe Revised 2016 WHO Classification of Acute Leukemias
The Revised 2016 WHO Classification of Acute Leukemias Robert P Hasserjian, MD Associate Professor Massachusetts General Hospital and Harvard Medical School Acute leukemias Aggressive hematopoietic neoplasms
More informationClinically Useful Next Generation Sequencing and Molecular Testing in Gliomas MacLean P. Nasrallah, MD PhD
Clinically Useful Next Generation Sequencing and Molecular Testing in Gliomas MacLean P. Nasrallah, MD PhD Neuropathology Fellow Division of Neuropathology Center for Personalized Diagnosis (CPD) Glial
More informationSUPPLEMENTARY INFORMATION
Supplementary Information S1 Frequency of DNMT3A mutations in hematologic disorders and their associated clinical phenotypes. Disease Patient population Frequency (%) Associated Clinical Characteristics
More informationGermline Testing for Hereditary Cancer with Multigene Panel
Germline Testing for Hereditary Cancer with Multigene Panel Po-Han Lin, MD Department of Medical Genetics National Taiwan University Hospital 2017-04-20 Disclosure No relevant financial relationships with
More informationClinical Grade Genomic Profiling: The Time Has Come
Clinical Grade Genomic Profiling: The Time Has Come Gary Palmer, MD, JD, MBA, MPH Senior Vice President, Medical Affairs Foundation Medicine, Inc. Oct. 22, 2013 1 Why We Are Here A Shared Vision At Foundation
More informationCorporate Medical Policy. Policy Effective February 23, 2018
Corporate Medical Policy Genetic Testing for FLT3, NPM1 and CEBPA Mutations in Acute File Name: Origination: Last CAP Review: Next CAP Review: Last Review: genetic_testing_for_flt3_npm1_and_cebpa_mutations_in_acute_myeloid_leukemia
More informationHematolymphoid lesions of the skin Part II Myeloid neoplastic proliferations Houston Society of Clinical Pathologists Symposium April 14, 2018
Hematolymphoid lesions of the skin Part II Myeloid neoplastic proliferations Houston Society of Clinical Pathologists Symposium April 14, 2018 Carlos A. Torres-Cabala, MD Associate Professor Chief, Dermatopathology
More informationClinical Grade Biomarkers in the Genomic Era Observations & Challenges
Clinical Grade Biomarkers in the Genomic Era Observations & Challenges IOM Committee on Policy Issues in the Clinical Development & Use of Biomarkers for Molecularly Targeted Therapies March 31-April 1,
More informationSchedule of Accreditation issued by United Kingdom Accreditation Service 2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK
2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK Haematopathology and Oncology Diagnostic Services (HODS) Addenbrookes Hospital Hills Road Cambridge CB2 0QQ Contact: Brian Warner Tel: +44
More informationSESSION 1 Reactive cytopenia and dysplasia
SESSION 1 Reactive cytopenia and dysplasia Falko Fend, Tübingen & Alexandar Tzankov, Basel 1 Disclosure of speaker s interests (Potential) conflict of interest none Potentially relevant company relationships
More informationTargeted Molecular Diagnostics for Targeted Therapies in Hematological Disorders
Targeted Molecular Diagnostics for Targeted Therapies in Hematological Disorders Richard D. Press, MD, PhD Dept of Pathology Knight Cancer Institute Knight Diagnostic Labs Oregon Health & Science University
More information